Clincosm LogoSign in Get a demo

Netrin-1 and Placenta Accreta

Sponsor
Assiut University (Other)
Overall Status
Completed
CT.gov ID
NCT04683562
Collaborator
(none)
34
Enrollment
1
Location
2
Arms
6
Actual Duration (Months)
5.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor. It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta. Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types. Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog). Its receptors have been linked to the processes of apoptosis and angiogenesis. In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis. In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells. Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer. Serum Netrin-1 levels were high in preeclamptic patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Pregnant women at 28-32 weeks
  • Other: at delivery
 N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
34 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Implication of Placental Netrin-1 Receptor DCC in the Pathophysiology of Placenta Accreta
Actual Study Start Date :
Dec 1, 2021
Actual Primary Completion Date :
Jun 1, 2022
Actual Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Normal pregnancy group

Other: Pregnant women at 28-32 weeks
Pregnant women at gestational age 28-32 weeks

Other: at delivery
women delivered at term
Other: Placenta accreta group

Other: Pregnant women at 28-32 weeks
Pregnant women at gestational age 28-32 weeks

Other: at delivery
women delivered at term

Outcome Measures

Primary Outcome Measures

  1. Placental Netrin-1 level [4 weeks]

    will be measured by using enzyme-linked immunosorbent assay (ELİSA) in placental homogenate

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Age between 20-40 years.

  • Singleton pregnancy.

  • Women with suspicion of PA by two-dimensional (2D) gray scale imaging and color Doppler flow mapping

Exclusion Criteria:

  • Multiple pregnancy,

  • Fetal anomalies,

  • Preterm premature rupture of membranes, or infection

  • Any medical disorders, such as thyroid dysfunction, hypertension, and gestational diabetes

  • Patients with known bleeding disorders or on anticoagulant therapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Woman's Health Hospital Assiut Egypt 71111

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mohammed Khairy Ali, Assistant professor, Assiut University
ClinicalTrials.gov Identifier:
NCT04683562
Other Study ID Numbers:
  • PA-NT1
First Posted:
Dec 24, 2020
Last Update Posted:
Aug 22, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Placenta Accreta

Study Results

No Results Posted as of Aug 22, 2022